BIOMARKER:

VHL mutation

A1 | Sensitive

C1 | Sensitive

C2 | Sensitive

C3 | Sensitive

C4 | Sensitive

D | Sensitive

A1 | Resistant

C1 | Resistant

C2 | Resistant

C3 | Resistant

C4 | Resistant

D | Resistant

Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

Neuroendocrine Tumor

CNS Tumor

HER2 Positive Breast Cancer

Glioblastoma

Cholangiocarcinoma

belzutifan

VHL mutation|Renal Cell Carcinoma|belzutifan

VHL mutation|Clear Cell Renal Cell Carcinoma|belzutifan

VHL mutation|Neuroendocrine Tumor|belzutifan

VHL mutation|CNS Tumor|belzutifan

VHL mutation|Glioblastoma|belzutifan

MK-3795

VHL mutation|Clear Cell Renal Cell Carcinoma|MK-3795

VHL mutation|Neuroendocrine Tumor|MK-3795

trastuzumab

VHL mutation|HER2 Positive Breast Cancer|trastuzumab

sunitinib

VHL mutation|Cholangiocarcinoma|sunitinib

everolimus

VHL mutation|Renal Cell Carcinoma|everolimus

doxorubicin hydrochloride

VHL mutation|Renal Cell Carcinoma|doxorubicin hydrochloride

pazopanib

VHL mutation|Clear Cell Renal Cell Carcinoma|pazopanib

VEGFR inhibitor

VHL mutation|Clear Cell Renal Cell Carcinoma|VEGFR inhibitor

Immunotherapy

VHL mutation|Renal Cell Carcinoma|Immunotherapy